Grantees of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have adapted a rapid and accurate new molecular typing strategy and used it to conduct one of the most comprehensive studies of adenoviruses ever performed in the United States.
Men who have prostate cancer are on average four times more likely to suffer a hip fracture, with rates rising to eight times in men aged 50 to 65, according to a study of more than 60,000 men published in the October issue of the urology journal BJU International. Danish researchers looked at 62,865 men aged 50 and over, with an average age of just under 67.
Accentia Biopharmaceuticals announces that it met with the Food and Drug Administration (FDA) on September_26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune™. The FDA has indicated its support for Accentia to submit an IND for a pivotal Phase 3 randomized controlled, multi-center clinical trial of Revimmune, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS).
UK Health Secretary Alan Johnson today announced a substantial £170 million expansion of psychological therapies to provide better support for people with mental health problems such as anxiety and depression.
October 15, 2007, marks the fifth annual National Latino AIDS Awareness Day. On this day, the National Institute of Allergy and Infectious Diseases (NIAID) pledges to continue working toward reducing the burden of HIV/AIDS in the Latino community in the United States.
When treating early-stage prostate cancer, intensity modulated radiation therapy spares the bladder significantly more from direct radiation when compared to 3-D conformal proton therapy , but the amount of rectal sparing is similar with both treatments, according to a study released in the October issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.
A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
A UNSW researcher has developed a world-first test which will radically improve cancer management. Professor Philip Hogg, the co-director of UNSW’s Lowy Cancer Research Centre, has developed the technology which will determine whether cancer cells are dying within one day of a patient’s treatment with radiation or chemotherapy.
Professor Sir Martin Evans, Professor of Mammalian Genetics at the School of Biosciences, Cardiff University, has won the 2007 Nobel Prize for Medicine. The Nobel Assembly at the Karolinska Institute, Sweden, announced this morning that Professor Sir Martin was one of three winners for “a series of ground-breaking discoveries concerning embryonic stem cells and DNA recombination in mammals.”
Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations. Although the 5-year survival rate for patients with early stage and local CRC approaches nearly 90%, survival is dramatically decreased by local recurrence and the development of distant metastases that primarily affect the liver, which are the predominant cause of CRC-related mortality.